Heart Failure in Type 2 Diabetes: Key Clinical Evidence and Treatment Insights

0
0
0

Heart Failure in Type 2 Diabetes: Key Clinical Evidence and Treatment Insights

Type 2 diabetes (T2DM) affects over 537 million people globally, and one of its most serious complications—heart failure (HF)—is increasingly recognized as a major health threat. As treatments for heart attacks and strokes have improved, HF has emerged as a more common first or subsequent cardiovascular (CV) event in people with T2DM. Adding to this focus, a class of diabetes drugs called sodium-glucose co-transporter-2 inhibitors (SGLT2is) has unexpectedly reduced HF hospitalizations in large clinical trials. These findings raise critical questions for patients and clinicians: Who is at high risk for HF in T2DM? How can we prevent it? And which treatments offer the most protection?

Type 2 Diabetes and Heart Failure Risk

HF is far more common in people with T2DM than in those without. A 2015 cohort study of 1.9 million people in The Lancet Diabetes & Endocrinology found that HF was the second most common first CV event in T2DM, accounting for 14.4% of cases—only behind peripheral arterial disease. Even more striking: A 2018 study of 3.25 million people in Circulation showed that the rate of HF hospitalization was 5 times higher in T2DM (12.4 per 1,000 person-years) than in people without diabetes (2.4 per 1,000 person-years).

Importantly, HF can develop in T2DM with or without blocked arteries (atherosclerotic cardiovascular disease, or ASCVD). While ASCVD (e.g., heart attacks) is a major driver of HF, research from the Health, Aging, and Body Composition Study found that HF incidence rises with age even in T2DM patients with no history of vascular disease. This suggests multiple pathways link T2DM to HF—including high blood sugar (hyperglycemia), high blood pressure (hypertension), kidney damage (diabetic nephropathy), nerve damage (autonomic neuropathy), and harmful changes to heart muscle proteins (glycosylation).

Blood Glucose and Heart Failure: A Strong Link

High blood sugar levels are a key contributor to HF risk. A 2018 Swedish cohort study of over 271,000 T2DM patients in the New England Journal of Medicine (NEJM) found that glycated hemoglobin (HbA1c)—a marker of long-term blood sugar control—was one of the strongest predictors of HF hospitalization. Patients with HbA1c levels above 8% had a 45% higher risk of HF than those with HbA1c below 7%.

For many T2DM patients, HF develops as “heart failure with preserved ejection fraction (HFpEF),” where the heart muscle becomes stiff and can’t relax properly (diastolic dysfunction). Researchers believe this stiffness stems from a cycle of inflammation: Comorbidities like T2DM, obesity, and hypertension trigger systemic inflammation, which damages the tiny blood vessels (microvasculature) in the heart. This damage reduces nitric oxide (a molecule that relaxes blood vessels) and impairs heart muscle function, leading to thickening (hypertrophy) and scarring (fibrosis). Over time, the stiff heart can’t pump effectively, causing HF symptoms like shortness of breath and fatigue.

Glucose-Lowering Treatments: Which Help (or Harm) Heart Failure?

Not all diabetes drugs are equal when it comes to HF risk. A 2015 meta-analysis of 14 trials (95,502 patients) in The Lancet Diabetes & Endocrinology found:

  • Higher HF risk: Peroxisome proliferator-activated receptor (PPAR) agonists (e.g., pioglitazone) increased HF risk by 42%. Dipeptidyl peptidase-4 (DPP-4) inhibitors (e.g., sitagliptin) raised risk by 25%.
  • Neutral risk: Insulin glargine, intensive glycemic control (e.g., targeting HbA1c <7%), and weight loss strategies did not affect HF risk.

The biggest game-changer for HF in T2DM has been SGLT2is—drugs that help the kidneys remove excess glucose from the blood. Four large trials (EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE) have consistently shown that SGLT2is reduce HF hospitalizations:

  • Empagliflozin (EMPA-REG): Cut HF hospitalization by 35% and CV death by 38% in high-risk T2DM patients (NEJM, 2015).
  • Canagliflozin (CANVAS): Reduced HF hospitalization by 33% (NEJM, 2017). In the CREDENCE trial (NEJM, 2019), canagliflozin lowered HF hospitalization by 39% in T2DM patients with chronic kidney disease.
  • Dapagliflozin (DECLARE-TIMI 58): Did not reduce overall CV events but cut the combined risk of CV death or HF hospitalization by 17%—driven entirely by a 27% drop in HF stays (NEJM, 2019).

Crucially, these benefits appeared early (within months of starting treatment) and were not linked to weight loss or blood sugar control alone. Researchers suspect SGLT2is work by reducing fluid buildup (lowering blood volume) and improving heart metabolism—effects that directly protect against HF.

Who Needs Primary Prevention for Heart Failure?

For T2DM patients without existing HF, identifying those at high risk is urgent. The 2018 Swedish cohort study (NEJM) found five strong predictors of HF hospitalization:

  1. Body mass index (BMI) outside the healthy range (too high or too low)
  2. Elevated HbA1c (poor blood sugar control)
  3. Low physical activity
  4. Current smoking
  5. Long duration of diabetes (10+ years)

These factors help clinicians target patients for early intervention—like SGLT2i treatment, blood pressure control, or lifestyle changes. However, risk prediction gets more complex when patients already have HF: The same study found that predictors shift (e.g., kidney function becomes more important), highlighting the need for personalized care.

What About Asian Patients?

While SGLT2is work similarly for glucose control in Asian and non-Asian T2DM patients, their HF benefits in Asian populations are less clear. The EMPA-REG trial suggested Asian patients gained more protection against major CV events (MACE) than the overall study group, but the CANVAS Program found no such difference. More research is needed to confirm whether SGLT2is reduce HF hospitalization equally in Asian and non-Asian T2DM patients—a critical question given that 60% of the global T2DM population lives in Asia.

The Future: Cardiometabolic Medicine

The link between T2DM, obesity, and CV disease demands a new approach to care: cardiometabolic medicine. This field integrates endocrinology (managing diabetes, obesity, and metabolism) with cardiology (preventing ASCVD and HF). Clinicians trained in cardiometabolic medicine can address the “big picture” for T2DM patients—combining blood sugar control with HF risk reduction, lifestyle counseling, and personalized drug therapy.

Conclusion

HF is now a leading cardiac concern for people with T2DM, even in those without blocked arteries. The good news is that SGLT2is offer robust protection against HF hospitalization, and risk prediction tools help target prevention to those who need it most. For clinicians, the takeaway is clear: Screen T2DM patients for HF risk (using BMI, HbA1c, activity levels, smoking, and diabetes duration), avoid drugs that raise HF risk, and prioritize SGLT2is for high-risk patients. For the future, integrating endocrinology and cardiology training will be key to tackling the growing burden of cardiometabolic disease.

  1. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine 2015;373:2117–2128. doi: 10.1056/NEJMoa1504720
  2. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. New England Journal of Medicine 2017;377:644–657. doi: 10.1056/NEJMoa1611925
  3. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine 2019;380:347–357. doi: 10.1056/NEJMoa1812389
  4. Shah AD, Langenberg C, Rapsomaniki E, et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people. The Lancet Diabetes & Endocrinology 2015;3:105–113. doi: 10.1016/S2213-8587(14)70219-0
  5. Khan H, Kalogeropoulos AP, Zannad F, et al. Incident heart failure in relation to vascular disease: insights from the Health, Aging, and Body Composition Study. European Journal of Heart Failure 2014;16:526–534. doi: 10.1002/ejhf.69
  6. McAllister DA, Read SH, Kerssens J, et al. Incidence of hospitalization for heart failure and case-fatality among 3.25 million people with and without diabetes mellitus. Circulation 2018;138:2774–2786. doi: 10.1161/CIRCULATIONAHA.118.034986
  7. Cooper LB, Yap J, Tay WT, et al. Multi-ethnic comparisons of diabetes in heart failure with reduced ejection fraction: insights from the HF-ACTION trial and the ASIAN-HF registry. European Journal of Heart Failure 2018;20:1281–1289. doi: 10.1002/ejhf.1223
  8. Rawshani A, Rawshani A, Franzén S, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine 2018;379:633–644. doi: 10.1056/NEJMoa1800256
  9. Heinzel FR, Hohendanner F, Jin G, et al. Myocardial hypertrophy and its role in heart failure with preserved ejection fraction. Journal of Applied Physiology 2015;119:1233–1242. doi: 10.1152/japplphysiol.00374.2015
  10. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. Journal of the American College of Cardiology 2013;62:263–271. doi: 10.1016/j.jacc.2013.02.092
  11. Udell JA, Cavender MA, Bhatt DL, et al. Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. The Lancet Diabetes & Endocrinology 2015;3:356–366. doi: 10.1016/S2213-8587(15)00044-3
  12. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. New England Journal of Medicine 2019;380:2295–2306. doi: 10.1056/NEJMoa1811744
  13. Marx N, McGuire DK. Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. European Heart Journal 2016;37:3192–3200. doi: 10.1093/eurheartj/ehw110
  14. Cosentino F, Grant P, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal 2020;41:255–323. doi: 10.1093/eurheartj/ehz486
  15. McMurray JJV, DeMets DL, Inzucchi SE, et al. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). European Journal of Heart Failure 2019;21:665–675. doi: 10.1002/ejhf.1432
  16. Cai XL, Ji LN. Treatment response between Asian and non-Asian patients with type 2 diabetes: is there any similarity or difference? Chinese Medical Journal 2019;132:1–3. doi: 10.1097/CM9.0000000000000012

doi: 10.1097/CM9.0000000000000732

Was this helpful?

0 / 0